Humana Inc. 10-Q Summary: Quarter Ended September 30, 2025
Business Context and Reporting Period
This summary covers Humana Inc.'s unaudited quarterly report (Form 10-Q) for the period ended September 30, 2025. Humana operates as a large accelerated filer in the health insurance and healthcare services sector, primarily serving Medicare Advantage, Medicare Part D, and Medicaid populations through its Insurance segment, and providing pharmacy, primary care, and home solutions through its CenterWell segment.
Key Financial Metrics
| Metric | Q3 2025 (3 Months) | Q3 2024 (3 Months) | YTD 2025 (9 Months) | YTD 2024 (9 Months) |
|---|---|---|---|---|
| Total Revenues | $32,649 million | $29,397 million | $97,149 million | $88,548 million |
| Net Income (Attributable to Humana) | $195 million | $480 million | $1,984 million | $1,900 million |
| Diluted EPS | $1.62 | $3.98 | $16.43 | $15.72 |
| Operating Income | $400 million | $728 million | $3,512 million | $3,105 million |
| Benefit Ratio | 91.1% | 89.9% | 89.3% | 89.2% |
| Operating Cost Ratio | 12.6% | 11.5% | 11.4% | 10.9% |
| Cash and Equivalents | $5,388 million | $2,221 million (Dec 2024) | N/A | |
| Long-Term Debt | $12,607 million | $11,144 million (Dec 2024) | N/A |
Material Changes vs. Prior Period
- Revenue Growth: Total revenues increased 11.1% year-over-year in Q3 2025, driven by a 9.9% increase in premiums revenue and a 45.1% increase in services revenue. Premium growth was fueled by higher per-member Medicare premiums (due to Inflation Reduction Act subsidies) and growth in state-based contracts and stand-alone PDPs.
- Profitability Decline: Net income attributable to Humana dropped 59.6% in Q3 2025 compared to Q3 2024. This decline was significantly impacted by non-recurring items, including a $63 million loss on the sale of a business, $267 million in value creation initiative charges (severance and consulting), and $97 million in put/call valuation adjustments related to minority interest investments.
- Expense Trends: Benefits expense rose 11.4% year-over-year, and the benefit ratio increased to 91.1% due to a shift in business mix toward higher-ratio state-based contracts and PDPs, partially offset by favorable prior-period medical claims development ($275 million in Q3). Operating costs increased 22.3% year-over-year, largely due to value creation charges and business mix changes.
- Liquidity: Cash and cash equivalents increased significantly to $5.4 billion from $2.2 billion at year-end 2024, driven by strong operating cash flows ($2.6 billion YTD) and net proceeds from investment securities sales.
Guidance, Outlook, and Risks
- Value Creation Initiatives: Management expects to incur additional charges in 2025 related to workforce optimization and external consulting as part of its value creation strategy.
- Regulatory Litigation (RADV): A significant legal victory was achieved on September 25, 2025, when a federal court vacated the CMS Final RADV Rule, finding it procedurally invalid. However, the company notes there can be no assurances regarding the final disposition of the lawsuit or future regulatory actions.
- Star Ratings Litigation: On October 14, 2025, a court rejected Humana's challenge to the 2025 Star Ratings. The company is considering its options, noting uncertainty regarding the outcome.
- Membership Trends: Individual Medicare Advantage membership declined 7.5% year-over-year due to strategic exits from unprofitable plans and counties. Conversely, Group Medicare Advantage and State-based contract memberships grew by 4.2% and 14.7%, respectively.
- Debt Management: In March 2025, the company issued $1.5 billion in new senior notes to repay maturing debt and fund general corporate purposes. The company maintains a $5.0 billion revolving credit facility with $4.99 billion available.
Investor Verification Checklist
- Impact of One-Time Charges: Verify the sustainability of earnings by excluding the $442 million in specific adjustments (value creation, loss on sale, put/call valuations) that depressed Q3 2025 results.
- Regulatory Risk Exposure: Monitor the status of the RADV litigation appeal and the potential financial impact of future CMS audit methodologies and Star Rating recalculations.
- Membership Mix Shift: Assess the long-term profitability implications of the strategic shift away from Individual Medicare Advantage toward State-based contracts and PDPs, which carry higher benefit ratios.
- Debt Maturity Profile: Review the company's ability to service its increased long-term debt load ($12.6 billion) amidst potential interest rate fluctuations.
- CenterWell Integration: Evaluate the operating cost ratio trends in the CenterWell segment, which increased to 93.9% in Q3 2025, driven by the v28 risk model revision and specialty pharmacy volume.